- Home
- Companies
- us virgin islands
- immune response
Refine by
Immune Response Suppliers Serving Us Virgin Islands
275 companies found
based inHillsborough, NEW JERSEY (USA)
LifeTein, located in Somerset, New Jersey, was founded in 2008 with a simple vision: understanding life sciences one protein at a time. This philosophy has formed the foundation of every peptide, protein, antibody, gene, and chemical project that we ...
based inGosselies, BELGIUM
SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line. SYnAbs' vision is to fill the gap on the marketplace for ...
Due to poor immunogenic properties and low molecular weight, your antigen is going to be eliminated in animal urine without generating any humoral immune response. That's why we've created SynAbs in the first place, ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
CYNK-001 is the only cryopreserved, allogeneic, off-the-shelf, natural killer (NK) cell therapy being developed from placental hematopoietic stem cells as a potential treatment option for various hematologic cancers, solid tumors, and infectious ...
based inxiamen, CHINA
XIAMEN SPACEGEN Co., Ltd. is a high-tech molecular diagnostic biology enterprise integrating R&D, production, sales and service. The company leads technological innovation guided by clinical needs ，providing high-quality and accessible molecular ...
Using high-throughput sequencing to test the coding regions and exon-intron junctions of five genes (MLH1, PMS2, MSH2, MSH6, EPCAM) in the germline panel, and the same five genes plus the BRAF V600E mutation in the tissue-based panel. Detection ...
based inLancaster, CALIFORNIA (USA)
Simulations Plus provides cutting-edge software solutions and consulting services designed to enhance drug discovery, clinical development, and regulatory submission processes. With over 25 years of experience, the company has established itself as ...
DILIsym integrates compound exposure with mechanisms of drug toxicity and inter-individual variability, offering insights into hepatotoxicity prediction for multiple species, including mice, rats, dogs, and humans. Its comprehensive sub-models cover ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
Immunosynthen is our novel immunostimulatory ADC platform designed to take ADCs beyond traditional cytotoxic drugs to targeted stimulation of the innate immune system. Through the safe and efficient delivery of a novel immunomodulatory STING ...
based inLublin, POLAND
We are a Polish biotechnology company with long manufacturing traditions. We have been present on the Polish and international markets since 1944. We are challenged and truly honoured to provide the leading, innovative medical solutions, and, due to ...
Name of the Medicinal Product: GAMMA anty-HBs 200, 200 IU/ml solution for injection. Qualitative And Quantitative Composition: Human hepatitis B immunoglobulin. 1 ml of the solution contains human protein not less than 100 mg, of which at least 85% ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Ondine Biomedical Inc. is a Canadian life sciences company that has become a global leader in photodisinfection-based therapies to prevent and treat a broad spectrum of infections, including those caused by drug-resistant pathogens. This patented ...
While most research efforts towards treating and preventing COVID-19 have centered on vaccine development and therapies for hospitalized patients, Ondine is seeking to offer a therapeutic approach to those patients who test positive but are not yet ...
based inSunnyvale, CALIFORNIA (USA)
We are developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases. Our Mission: To improve the lives of patients with cardiovascular and pulmonary diseases through the development of ...
The investigational CardiAMP™ Cell Therapy is designed to be a comprehensive biotherapeutic heart failure solution, incorporating: a proprietary molecular diagnostic to characterize the potency of a patient’s own bone marrow cells and ...
based inCambridge, MASSACHUSETTS (USA)
The human body is an ecosystem. Trillions of microbes call us home. They form the human microbiome, which performs critical functions that preserve our health including modulating our immune system and providing colonization resistance against ...
From Ruslan Medzhitov's discovery of toll-like receptors (TLRs) as the key immune system receptors that detect infection, which spawned the field of innate immunity, to Dan Littman's efforts to identify and clone ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
This is in part due to dynamics in the tumor microenvironment, wherein regulatory T cells [Tregs] proliferate and suppress the immune responses to tumor cells. The Treg is a type of T cell that is important in ...
based inCambridge, MASSACHUSETTS (USA)
Vaxxas is commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will be fundamental to help the world in rethinking what's ...
Vaxxas has developed novel technologies that enable vaccines to be applied to the tips of the microprojections under sterile conditions. The HD-MAP delivers the vaccine on its microprojections efficiently to the high density populations of ...
based inNew York, NEW YORK (USA)
We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we seek to capitalize on ...
Our licensed gene therapy, CO-sTiRNA™, is a dual-action STAT3 inhibitor. STAT3 is a gene that drives tumor cell growth and anti-tumor immune suppression. CO-sTiRNA™ is a highly selective and targeted gene therapy that silences the ...
based inDurham, NORTH CAROLINA (USA)
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable, bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. Humacyte ...
Humacyte’s platform technology has the potential to change the lives of countless people around the world by overcoming the current limitations in existing standards of care. We are leveraging our scalable technology platform to develop ...
based inLimerick, PENNSYLVANIA (USA)
Rockland Immunochemicals, Inc. offers a robust catalog of antibodies to suit any project. No matter the context—basic research to disease therapy, phosphorylated to methylated, and beyond—Rockland embraces the challenge to design, produce, validate, ...
Our list of services includes antigen consultation, peptide or protein antigen production, antibody generation, antibody purification, and conjugation to reporter molecules such as peroxidase or fluorochromes. We are experts in generating antibodies ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
Our AIM nanoparticle technology enables the development of immunotherapies that orchestrate specific T cell function and trigger a precise immune response against disease. An AIM™ Adoptive Cellular Therapy ...
based inSan Diego, CALIFORNIA (USA)
Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. Stemedica has developed a proprietary ...
There are two types of cells currently used for investigating progenitor cell therapies for degenerative diseases: autologous and allogeneic. Autologous progenitor cells are derived from the patient being treated. They are retrieved surgically, ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Acuitas is a private company based in Vancouver, British Columbia and was founded in February 2009. We are partnered with multiple pharmaceutical companies, biotechnology companies and academic institutes to advance nucleic acid therapeutics to the ...
Proteins are the “workhorses” within cells responsible for metabolic processes, transport processes and structural elements. They are coded by genes on DNA and this code is transcribed into a message (messenger RNA or mRNA) within the ...
based inWuhan, CHINA
Mulei (Wuhan) New Material Technology Co. Ltd is a scientific and technological company integrating product research and development manufacturing and trading of chemical intermediates, specialized in organic intermediates, pharmaceutica ...
Common Name: Levamisole (hydrochloride). CAS Number: 16595-80-5. Molecular Weight: 240.752. Boiling Point: 344.4°C at 760 mmHg. Molecular Formula: C11H13CIN2S. Melting Point: 226-231°C. Flash Point: ...
based inBellinzona, SWITZERLAND
MV Biotherapeutics (MV Bio) is a early stage Swiss biotherapeutics company, and a spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland. MV Bio is developing first-in-class mucosal immune enhancers for the ...